Sydnexis Appoints Erin Horn as Vice President, Head of Market Access

Sydnexis has announced the appointment of Erin Horn as Vice President, Head of Market Access.

Ms. Horn will lead Sydnexis’ market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, Ms. Horn has a track record of commercial success in traditional and specialty ophthalmic pharmaceuticals, Sydnexis stated in a company news release. 

“We are thrilled that Erin has joined Sydnexis in pursuit of our mission. Erin brings a wealth of knowledge, expertise, and direct experience with market access customers and organizations that is unsurpassed in ophthalmology. She is a dynamic addition to the Sydnexis leadership team and we are extremely excited for her future success,” said Nick Ruth, Chief Commercial Officer at Sydnexis.

“Joining the Sydnexis team presents an opportunity to help advance a treatment for pediatric progressive myopia and enhance the long-term quality of life of children,” Ms. Horn said. “I'm excited to create affordable access to a novel treatment that will serve a growing unmet need for children and their families. I look forward to working with this incredible team.”

Prior to joining Sydnexis, Ms. Horn held roles at several leading companies, including Iveric Bio (an Astellas Company), Aerie, Alcon, and Novartis.

Sydnexis is currently conducting a pivotal phase 3 clinical trial evaluating its proprietary low-dose atropine formulation for the treatment of progressive myopia in pediatric patients. Phase 3 data is expected to be available in the second quarter of 2024.